Lydia(Lyuqin) Chen

Lydia (Lyuqin) Chen has worked in a variety of roles in the scientific field over the past few years. In 2021, they began working as a Senior Scientist at NeuBase Therapeutics, Inc., where they co-lead a team to develop gene editing pipelines using CRISPR/cas9, PNA/ODN in hematopoietic stem cells (CD34+), iPSC, and cancer cells. Lydia(Lyuqin) also facilitates project progress, coordinates deadlines and priorities, and studies and compares different gene editing technologies in the market.

In 2019, they began working as an Assistant Instructor and Postdoctoral Associate at the University of Pittsburgh. In this role, they identified and validated novel druggable targets in breast cancer using cell-based assays and in vivo mouse models. Lydia(Lyuqin) also designed and planned high-throughput screening assays using siRNA and shRNA and was the recipient of a Dean Scholarship.

In 2017, they began working as a Postdoctoral Researcher at Stanford University School of Medicine. In this role, they performed extensive troubleshooting to improve CRISPR/Cas9 targeting efficiency in human iPSC, successfully generated several knock-in reporter and conditional knock-out human iPS cell lines, and provided technical support on CRISPR/Cas9 technology within four interdisciplinary research groups. Lydia(Lyuqin) also established a method for high-efficiency induction of hiPS cell differentiation into a different type of neuron and led a team to study the pathogenic mechanisms of Fragile X syndrome disease using patient iPSC.

Lydia (Lyuqin) Chen is currently enrolled in the University of Pittsburgh Katz Graduate School of Business, starting in 2021. From 2011 to 2016, they obtained a Doctor of Philosophy - PhD in Genetics from the University of Chinese Academy of Sciences, SIBS. Prior to that, they completed a Bachelor's degree in Agriculture Biotechnoloy at South China Agricultural University from 2007 to 2011. Lydia(Lyuqin) is also expected to obtain a certification in Drug Development from Coursera in 2022, and is currently enrolled in a Drug Discovery course from Coursera.